This page shows the latest lambrolizumab news and features for those working in and with pharma, biotech and healthcare.
Pembrolizumab (formerly lambrolizumab; MK-3475) is one of the highlights of Merck's R&D pipeline and is being evaluated across more than 30 types of cancer, with peak sales estimated
MK-3475 was previously known as lambrolizumab but a new name is currently under review.
For its part, Merck said the agreement would allow it to focus on its later-stage oncology projects, including the much-touted PD-1-targetting cancer immunotherapy lambrolizumab (MK-3475) and
PD-1 is something of a hot target at the moment, with candidates such as Merck &Co's lambrolizumab and Bristol-Myers Squibb's nivolumab attracting a lot of attention thanks
For T-VEC, interest is building around the concept of combining the virus with PD-1-targeting immunotherapies such as BMS' nivolumab and Merck &Co's lambrolizumab, which also generated new
Positive study results for anti-PD-1 candidates lambrolizumab and nivolumab. Merck &Co and Bristol-Myers Squibb (BMS) both presented positive phase III data for their anti-PD-1 melanoma candidates ... As it is likely to be second to market behind
More from news
Approximately 1 fully matching, plus 6 partially matching documents found.
Dice Medical Communications is an independent communications agency that works with our clients to help launch, build, and continually develop...